A Descriptive Cross-sectional Study of Pain in Patients with Neuroendocrine Tumors Abstract #1409

Introduction: Pain is a feared symptom in cancer patients and is reported in 30% of patients during treatment and in 70-90% with advanced disease.
Aim(s): Our aim was to determine the extent and the severity of pain in outpatients with NET as this has previously never been investigated.
Materials and methods: We conducted a cross-sectional survey of 207 NET patients between March 2014 and March 2015 at our tertiary NET Center. We used a validated questionnaire to investigate the prevalence, severity and character of pain along with demographic, clinical and pathological data from medical records.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: PhD Gitte Dam

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Assistant Profes Po Hien Ear
Authors: Ear P H, Tran C, Li G, Kaemmer C, ...
#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD, Lecture Carmen Sorina Martin
#3054 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Erin Laing
#145 Paragangliomas: a series of five cases
Introduction: Paraganglioma is a rare extraadrenal neuroendocrine tumor, composed of chromaffin cells and arising from the neural crest. The head, neck, and retroperitoneum are the most common sites for paraganglioma.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Assoc. Professor Catalina Poiana
Authors: Poiana C, Carsote M, Paun D, Hortopan D, ...
#317 Paraganglioma: Gallium-68 DOTOTATE PET CT Scanning, a Useful Addition to MIBG Scanning in Metastatic Disease
Introduction: Nuclear imaging forms an important part of the assessment of chromaffin cell tumors. MIBG scintigraphy has been available for some time, while 68Ga-DOTATATE PET CT is increasingly utilized.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll